Prostate cancer is one of the most commonly diagnosed cancers and the second leading cause of cancer deaths in Americans. The high mortality rate is mainly attributed to the invasiveness and metastasis of advanced prostate cancer. Targeting the molecules involved in metastasis could be an effective mode of treatment for prostate cancer. In this study, the therapeutic potential of siRNAmediated targeting of matrix metalloproteinase-9 (MMP-9), urokinase plasminogen activator receptor (uPAR), and cathepsin B (CB) in prostate cancer was carried out using single and bi-cistronic siRNA-expressing constructs. Downregulation of MMP-9, uPAR, and CB inhibited matrigel invasion, in vitro angiogenesis and wound-healing migration ability of PC3 and DU145 prostate cancer cell lines. In addition, the siRNA treatments induced apoptosis in the tumor cells as determined by TUNEL and DNA laddering assays. An attempt to elucidate the apoptotic pathway showed the involvement of FAS-mediated activation of caspases-8 and -7. Further, mice with orthotopic prostate tumors treated with siRNA-expressing vectors showed significant inhibition in tumor growth and migration. In conclusion, we report that the siRNA-mediated knockdown of MMP-9, uPAR, and CB inhibits invasiveness and migration of prostate cancer cells and leads to apoptosis both in vitro and in vivo.
Introduction
Prostate cancer is the most commonly diagnosed malignancy and the second leading cause of cancer mortality in the United States. 1 During the year 2008, nearly 186 000 men were newly diagnosed with prostate cancer and B28 000 estimated deaths related to prostate cancer were reported. Localized and early diagnosed tumors are effectively treated by prostatectomy or radiation therapy. However, a significant number of the patients treated with prostatectomy suffered relapse. [2] [3] [4] Most of the patients with relapsed disease initially respond to the hormonal ablation therapy, but they eventually progress to hormone refractory prostate cancer and metastases to other organs, which no longer responds to hormone ablation therapy. [5] [6] [7] Metastasis is considered to be an aggressive fatal step in the progression of prostate cancer, which primarily migrate to the bone through lymphatic and hematogeous routes and potentially lead to death of the patients. 8 Aggressiveness of tumor is mainly dependent on the extent it can invade and metastasize from the primary tumor site and establish itself at a distant site. Metastasis is a complex process involving adhesion of cell to the extracellular matrix (ECM), degradation of ECM components to release the cells from the primary tumor mass, migration and establishment of tumor cells at the secondary target. 9 Dissolution of ECM components, key regulator factors during metastasis, is primarily achieved through the action of several proteolytic enzymes, released either by the tumor or stromal cells present in the tumor microenvironment. Under normal physiological conditions, these cellular proteases are under tight regulatory control; however, in case of metastatic tumors, these control mechanisms are either lost or imbalanced. 10 Moreover, studies have shown a high-degree correlation between the enhanced expression and activity of several cellular proteases to the metastatic behavior of the tumor. 11 Cellular proteases are generally subdivided as serine, cysteine, aspartic, and matrix metalloproteinases (MMP). Among several proteases, MMP's, urokinase plasminogen activator (uPA) system, and cathepsins have a major function in ECM degradation either by acting independently or by activating other protease in the breakdown of extracellular proteins contributing to the tumor migration and metastasis. [12] [13] [14] The uPA system (uPA and its receptor, urokinase plasminogen activator receptor (uPAR)) attracted most of the research due to the multifunctional role in cell differentiation, proliferation, cell adhesion, signaling, and so on. Despite activating uPA, uPAR is associated with various other cell surface molecules, especially the integrins, indicating its role in cell adhesion and migration as well as a signal transducer, 11, 15 which regulate various genes involved in cell proliferation, survival, and apoptosis. 14, [16] [17] [18] Even though both uPA and uPAR are expressed in normal and tumor cells, several studies have shown that the activity of uPA and the expression of its receptor are elevated or aberrantly expressed in many malignant tumors including prostate cancer. 15 Along with uPA/uPAR system, MMP, zinc-dependent proteases, also have a major function in proteolytic degradation of ECM components and aid in tumor invasion and metastasis. MMP, secreted as latent zymogens, are activated by plasmin and their activity is regulated by a family of tissue inhibitors of metalloproteinase. 19 During tumor metastasis, the balance between the active protease and their inhibitors is disrupted, generally leading to an elevated MMP expression. Overexpression of MMP is associated with various cancer metastases including those of breast, colon, head and neck, and lung. [20] [21] [22] In addition to ECM degradation, MMP also induces the release of various growth factors, such as VEGF, which stimulate angiogenesis. 23, 24 Apart from the extracellular proteases, several intracellular proteases are also actively involved in tumor migration and invasion. Cathepsins make up a group of cysteine proteases that are located in lysosomes and function both as an exopeptidase and endopeptidase. 25 These cathepsins are actively involved in tumor angiogenesis, apoptosis, and inflammatory response, either directly by degrading ECM components such as fibronectin, type I and IV collagen, laminin, or indirectly by activating other proteases such as MMP or the uPA. 26, 27 Increased expression of cathepsin B (CB) has been reported in various cancer types, including prostate cancer. 28 Further, as an intracellular protein, it is also involved in various intracellular proteolysis events and activation of signaling cascades. 28 The crucial roles played by MMP-9, uPAR, and CB, either individually or in combination with other proteases, in the tumor environment make these molecules highly desirable targets as therapeutic agents. Researchers have successfully blocked or downregulated the expression of these molecules through neutralizing antibodies, 29, 30 specific inhibitors, 31, 32 and antisense oligonucleotides. [33] [34] [35] [36] These strategies were shown to successfully inhibit tumor development in various cancer scenarios. Recently, RNA interference has emerged as a highly efficient method for silencing gene expression. RNA interference technology comprises a sequencespecific post-transcriptional gene silencing using a double-stranded RNA and shares sequence homology with the targeted gene. 37 This study was aimed to target MMP-9, uPAR, and CB, using siRNA-expressing vectors, in prostate cancer cells in both in vitro and in vivo conditions. In this study, we have shown that plasmid vector expressing siRNA for MMP-9, uPAR, and CB effectively abrogated invasion and migration of prostate cancer cells. Further, we have also shown that downregulation of MMP-9, uPAR, and CB expression induces apoptotic cell death and inhibits tumor growth and migration under in vivo conditions.
Materials and methods
Cells lines, siRNA vectors, and transfection conditions Human prostate cancer cell lines, PC3 and DU145 cell lines, were obtained from the American Type Culture Collection (Manassas, VA) and grown in F-12/K and DMEM/F-12K (1:1) media, respectively, containing 10% fetal bovine serum and 1% penicillin/streptomycin. All cell lines were maintained in a 37 1C incubator in a 5% CO 2 -humidified atmosphere. In this study, mono-cistronic constructs expressing MMP-9 (pM), uPAR (pU), and CB (pC) siRNAs individually, and two bi-cistronic constructs expressing siRNA in combination of MMP-9 and uPAR (pUM) as well as MMP-9 and CB (pCM) were used. The shRNA used in this study were expressed under the control of cytomegalovirus promoter in pcDNA3 vector (Invitrogen, San Diego, CA). Target gene sequences and construction of the above siRNA vectors were described in our earlier work. 38, 39 All transfections were performed using Fugene HD Transfection Reagent (Roche Molecular Biochemicals, Indianapolis, IN) as per the manufacturer's instructions. Briefly, a day before transfection, 3 Â 10 5 cells were seeded in a six-well culture plate and incubated at 37 1C incubator in a 5% CO 2 -humidified atmosphere. Transfection complex comprising 2 mg of shRNA-expressing plasmid and 6 ml of FUGENE HD transfection was added per each well and was further incubated for 48-72 h at 37 1C incubator in a 5% CO 2 -humidified atmosphere.
RT-PCR analysis
After 48 h of transfection, total RNA was extracted from the transfected cells using TRIZOL reagent (Invitrogen) as per the standard protocol. DNase-treated RNA was used as a template for reverse transcription (RT) reaction (Invitrogen) followed by PCR analysis using specific primers for MMP-9, uPAR, CB, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The amplified products were analyzed on agarose gel.
Gelatin zymography
The enzymatic activity and molecular weight of electrophoretically separated forms of MMP-9 were determined from the conditioned media by gelatin zymography. Briefly, 48 h after transfection, the cells were washed with phosphate-buffered saline (PBS) and incubated in serumfree medium for another 16 h. The serum-free (conditioned) media were assayed for gelatinase activity using 10% SDS gels containing gelatin (0.1 mg ml
À1
). Gels were incubated overnight in Tris-CaCl 2 buffer, pH 7.6 and stained with amido black (Sigma Aldrich, St Louis, MO).
Western blot analysis
After transfection, the cells were washed with PBS and lysed in cell lysis buffer (Tris-buffered saline, 20 mM EDTA and 0.1% Triton X-100 containing 1 mM PMSF and proteinase inhibitors). Equal amounts of protein were fractionated on SDS-PAGE and immunoblotted with primary antibodies, followed by incubation with speciesspecific horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA). Detection of signals was carried out using ECL enhanced western blotting detection system (Amersham Pharmacia, Piscataway, NJ) and autoradiography using X-ray films. The following antibodies were used: anti-uPAR (American Diagnostics Inc., Greenwich, CT), anti-CB (Athens Research and Technology, Athens, GA), anti-GAPDH (Abcam, Cambridge, MA), Fas-ligand (Abcam), XIAP, caspase-7, caspase-8, and cleaved caspase-8 (Cell Signaling Technology Inc., Beverly, MA). Antibodies against FAS, FAS-associated death domain (FADD), Bcl-2, Bax, total and phospho forms of ERK, Akt were obtained from Santa Cruz Biotechnology.
Cell proliferation assay
Viability of DU145 and PC3-transfected cells was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Seventy-two hours after transfection, B10 000 cells were seeded in 96-well plates and incubated for another 24 h. MTT (Sigma Aldrich) was added to the culture medium in each well at a concentration of 500 mg ml
À1
, and plates were incubated for 4 h at 37 1C. DMSO was added to each well and mixed vigorously to completely dissolve the dark blue crystals. Absorbance was measured at 555 nm (Benchmark, Bio-Rad, Hercules, CA).
Matrigel invasion assay
After 72 h of transfection, cells were detached, washed twice in PBS and B1 Â 10 5 cells suspended in serum-free medium were seeded in the upper chamber of a Transwell insert (8-mm pores) coated with matrigel (1 mg ml À1 ) (Collaborative Research Inc., Boston, MA). The lower chamber was filled with 700 ml of complete medium. After 18 h of incubation period, the non-migrated cells in the upper chamber were gently scraped away, and invaded cells present on the lower surface of the insert were stained with Hema-3 (Fisher Diagnostics, Middletown, VA). Photographs of the invaded cells were taken with a light microscope (Olympus IX-71, Minneapolis, MN).
In vitro angiogenesis assay Conditioned media after incubating the transfected cells in serum-free media for 16 h was collected and centrifuged to clear the cell debris. Approximately, 8 Â 10 3 human microvascular endothelial cells (HMECs) were cultured in the conditioned medium in 96-well plates for 48 h. After the incubation period, medium was removed and cells were stained with Hema-3 stain and observed under light microscope.
Wound-healing migration assay
The scratch motility assay was used to measure twodimensional cancer cell movement as described earlier. 40 Transfected cells were grown to full confluence in six-well plates. A scratch was made on the cell monolayer using a sterile 200 ml pipette tip. The monolayer was washed twice and incubated for another 18 h in complete medium. Cells were stained with Hema-3 stain and assayed by visualization under a light microscope (Olympus IX-71).
Apoptosis assays
In situ terminal deoxytransferase-mediated dUTP nick endlabeling (TUNEL) assay (Roche Molecular Biochemicals) was used to detect apoptosis of the transfected cells. Transfections were carried out in Lab-Tek II eight-well chamber slides (Nalge Nunc International, Naperville, IL) and processed as per the manufacturer's instructions. Positively stained, fluorescein-labeled cells were visualized and photographed using fluorescence microscopy. Apoptosis was also confirmed by DNA laddering assay by isolating DNA from the transfected and control cells as per the method described. 41 
Animal experiments
All animal experiments were performed in compliance with the institutional guidelines set by the Institutional Animal Care and Use Committee at the University of Illinois College of Medicine at Peoria. Athymic male nude mice (nu/nu; 5-6 weeks of age) were obtained from Harlan Sprague-Dawley (Indianapolis, IN). Orthotopic implantation was carried out as described earlier. 42 Briefly, after total body anesthesia with ketamine (50 mg kg
À1
) and xylazine (10 mg kg À1 ), a low midline incision was made in the lower abdomen. A suspension of 1 Â 10 6 PC3 cells, with luciferase reporter gene, in 20 ml PBS was injected into a lateral lobe of the mouse prostate. After 7 days of implantation, the tumors were injected with B150 mg of the respective plasmid-expressing siRNA. The primary tumor growth and sites of metastasis were determined by injecting luciferin (intra-peritoneal) at weekly intervals and examining the mice in Xenogen in vivo Imaging System (Xenogen, Alameda, CA). The primary prostate tumor was excised, fixed in formalin, and embedded in paraffin for hemtoxylin staining and immunohistology experiments as described earlier. 42 
Statistical analysis
Results were analyzed using two-tailed Student's t-test to assess statistical significance. The differences were considered as statistically significant when Po0.05. Densitometry analysis was performed using ImageJ software (National Institutes of Health) to quantify the signal (band) intensities.
Results
Downregulation of MMP-9, uPAR, and CB at the RNA and protein levels The expression and activation of MMP-9, uPAR, and CB is known to have an important function in invasion, survival, and progression of human tumors. Moreover, our earlier reports also supported the association of these proteases in breast, lung, glioma, and others cancer Targeting MMP-9, uPAR, and cathepsin B AK Nalla et al metastatic models. 38, 39 Therefore, in this study, we investigated the role of MMP-9, uPAR, and CB in two highly aggressive human prostate cancer cell lines, PC3 and DU145. We have used plasmid vectors expressing siRNA for MMP-9 (pM), uPAR (pU), and CB (pC), both individually and in combination of MMP 9/uPAR (pUM) and MMP-9/CB (pCM) to inhibit expression of the respective protein(s). RT-PCR analysis of the total RNA extracted from transfected cells showed a significant reduction in the mRNA levels of MMP-9, uPAR, and CB in the cells transfected with pM, pU, and pC, respectively. Further, transfection with bi-cistronic vectors, pUM and pCM inhibited both of the target genes simultaneously and specifically (Figures 1a and b) . The specificity of the plasmids used was demonstrated by comparing the GAPDH mRNA levels as internal control. We further determined the effect of these plasmids on the expression of uPAR and CB proteins as well as enzymatic activity of MMP-9. Western blot analysis of the total cell lysate collected from cells transfected with pU and pC showed a significant reduction of uPAR and CB proteins, respectively, when compared with the control and cells transfected with empty vector (pEV). Targeting two molecules using a bi-cistronic constructs proved to be effective in simultaneous downregulation of both the target genes as well as inhibiting the target molecules more efficiently than mono-cistronic constructs (Figure 1c) . Further, MMP-9 activity in the conditioned media collected from the transfected cells were examined by gelatin zymography. Cells that were transfected with pM, pU, pC, pUM, and pCM showed a significant reduction in MMP-9 enzymatic activity when compared with the control or pEV-transfected cells. However, we observed low or no significant changes in the levels of MMP-2 enzymatic activity in the transfected cells (Figure 1d ). Quantitative analysis of uPAR and CB protein signals by densitometry revealed significant decreases in uPAR and CB levels by 63 and 60% in PC3 cells transfected with pUM and pCM, respectively (Figure 1e) . Although in the case of DU145 cells transfected with pUM and pCM, the uPAR and CB protein levels were reduced by 59 and 64%, respectively. GAPDH protein levels showed that equal quantities of protein were loaded.
Effect on cell proliferation, ERK, and Akt activation MTT assay was carried out to determine the cell proliferation index in the transfected cells. Cell proliferation was significantly reduced in both PC3 and DU145 cells transfected with pM, pU, pC, pUM, and pCM compared with control and pEV-transfected cells (Figure 2a) . We further analyzed the effect of the downregulation of MMP-9, uPAR, and CB on ERK and Akt signaling molecules, which are considered as major survival molecules. Western blotting analysis was performed to detect the total and phosphorylated levels of ERK and Akt in the transfected cells using specific antibodies. No significant difference was observed in the total ERK and Akt levels in the transfected cells; however, phosphorylation of Akt decreased significantly in the cells treated with pM, pU, pC, pUM, and pCM when compared with the parental cells or cells treated with pEV (Figures 2b  and c) . In contrast to this, we observed significant increase in the phosphorylation of ERK1 (p44) and ERK2 (p42) in cells transfected with pM, pU, pC, pUM, and pCM when compared with control and pEVtransfected cells (Figures 2b and c) .
Downregulation of MMP-9, uPAR, and CB reduced tumor invasion, in vitro angiogenesis and migration To determine the functional significance of MMP-9, uPAR, and CB in prostate cancer cell lines, we compared the matrigel invasion, angiogenesis, and wound-healing migration ability of the transfected cells to the control cells. The ability of the transfected cells to invade the matrigel-coated filters was significantly decreased when compared with controls. The most significant decrease in invasive ability was observed in cells transfected with the bi-cistronic vectors (Figure 3a) . Quantitative analysis showed that only 19 and 25% of PC3 cells transfected with pUM and pCM, respectively, invaded through matrigel-coated transwell insert when compared with controls ( Figure 3b ). Similar observations were even made in DU145 cells where only 28 and 32% of pUMand pCM-transfected cells, respectively, invaded the matrigel-coated transwell insert when compared with controls. Moreover, nearly 40% of the PC3 and DU145 cells transfected with pM, pU, and pC invaded through matrigel-coated transwell compared with control and pEV-transfected cells. Well-defined capillary network formation was observed when HMEC were cultured in conditioned media collected from control or pEVtransfected cells. In contrast, the conditioned media collected from transfected cells failed to induce the capillary network formation of HMEC (Figure 3c ). The induction of capillary like network by HMEC grown in cancer cell conditioned media was quantified by counting the number of branching points. Conditioned media from pUM-and pCM-transfected PC3 cells showed 87 and 90% reduction in branching points, respectively, compared with controls (Figure 3d ). Whereas the conditioned media of pUM-and pCM-transfected DU145 cells showed a decrease by 84 and 81%, respectively, in the induction of branching points compared with controls ( Figure 3d ). Apart from significant inhibition in matrigel invasion, the transfected cells also showed reduced cell mobility as determined by scratch wound-healing migration assay. Microscopic examination showed that the control and pEV-transfected cells migrated prominently toward each other after 18 h of scratch. In contrast, the migration of the cells transfected with plasmid expressing siRNA were significantly reduced (Figure 4a) . The difference in distance migrated by controls between 0 and 18 h was measured and compared with that of the transfected cells. Quantification of the wound-healing migration assay illustrated that migration of PC3 cells transfected with pUM and pCM was decreased by nearly 54 and 59%, respectively, when compared with control and pEV-transfected cells (Figure 4b ).
Whereas the migration of DU145 cells transfected with
Targeting MMP-9, uPAR, and cathepsin B AK Nalla et al pUM and pCM was reduced by B70% compared with the respective controls (Figure 4b ).
Downregulation of MMP-9, uPAR, and CB induces apoptosis With the MTT assay showing a significant inhibition in cell proliferation, we made an attempt to determine the possible induction of apoptosis in MMP-9, uPAR, and CB downregulated prostate cancer cells by carrying out TUNEL and DNA laddering assays. In TUNEL assay, the cells were visualized under a fluorescent microscope using appropriate filter sets. The characteristic green fluorescence emission was prominently observed in cells transfected with pM, pU, pC, pUM, and pCM, which indicates the apoptotic nature of the cells. No such emission was observed in the non-apoptotic cells, which were primarily the control and pEVtransfected cells (Figure 5a ). Further evidence was provided by carrying out a DNA laddering assay to determine the fragmentation of cellular DNA, a characteristic feature of apoptotic cells. Agarose gel electrophoreses of the total DNA isolated from cells transfected with pM, pU, pC, pUM, and pCM showed the characteristic pattern of DNA laddering, whereas the same was not observed in control and pEV-transfected cells (Figure 5b ). Both high as well as low molecular Figure 1 siRNA-mediated downregulation of MMP-9, uPAR, and cathepsin B at the RNA and protein levels. PC3 and DU145 (prostate cancer cell lines) were transfected with either empty vector (pEV) or plasmids encoding siRNA for MMP-9 (pM), uPAR (pU), and cathepsin B (pC) (mono-cistronic) or in combination, pUM and pCM (bi-cistronic). (a) After 48 h of transfection, total RNA extracted from controls and transfected cells were used as a template for RT-PCR analysis using MMP-9, uPAR, and CB-specific primers. GAPDH primers were used to verify the usage of equal amount of total RNA during cDNA synthesis. Targeting MMP-9, uPAR, and cathepsin B AK Nalla et al weight DNA fragmentation was noticed in the transfected cells.
Apoptotic pathway
We then made an attempt to determine the possible molecules or the pathway involved in inducing apoptosis in the cancer cells by downregulating MMP-9, uPAR, and CB. Western blot analysis of the cell lysates revealed that the downregulation of MMP-9, uPAR, and CB activated several pro-apoptotic molecules (including Bax and caspases) and inhibited the expression of anti-apoptotic molecules mainly XIAP and Bcl-2 ( Figure 6 ). With the activation of pro-apoptotic molecules, we further attempted to determine the involvement of caspases in the induction of apoptosis in PC3 and DU145 cells. Figure 6 indicated that the downregulation of MMP-9, uPAR, and CB in prostate cancer cells induced cleavage of caspase-8 and caspase-7. In contrast, the respective cleaved products were comparatively low in the control and pEV-transfected cells. We next determined the involvement of various upstream molecules involved in the activation of caspase-8 and extrinsic apoptotic pathway. The levels of FAS and FAS-ligand were observed to be significantly increased (up to twofold) in cells transfected with pM, pU, pC, pUM, and pCM when compared with control and pEV-transfected cells (Figures 6b and c) . The downstream process involved in the Fas/Fas-L system is its association with death domain receptors. Western blot analysis showed an increase in the expression levels of FADD levels in the cells transfected with siRNA- Targeting MMP-9, uPAR, and cathepsin B AK Nalla et al expressing plasmids when compared with controls ( Figure 6 ). Quantification of the signals by densitometry analysis showed more than three-and twofold increase in the FADD expression levels in PC3 (Figure 6b ) and DU145 (Figure 6c ) cells, respectively, transfected with bi-cistronic shRNA plasmids (pUM and pCM). FADD serves as a single transducer of Fas-induced apoptosis, where the cytosolic domain binds to capsase-8, to transduce death signal.
Animal experiments
Given our in vitro results, we made an attempt to determine the effect of these plasmid-based siRNA constructs in vivo. PC3-M cells with lucfierase reporter gene were inoculated in the lateral lobe of mouse prostate. Seven days post-inoculating PC3 cells into the lateral lobe of mouse prostate, the animals were injected with pM, pU, pC, pUM, pCM, and pEV. The control mice (pEV treated) were killed 3 weeks after implantation, as was necessitated by the morbidity resulting from the tumors that had formed in control groups. Prostate tumor growth and progression was monitored at weekly intervals by measuring the luciferase activity using the Xenogen in vivo imaging system. Photon counts from the tumor region were measured on days 7, 15, and 22. Control mice developed larger tumor at 21 days postimplantation compared with mice treated with siRNAexpressing constructs (Figure 7a ). On the basis of the tumor volume and luciferase activity, the control mice were killed at 22 days (third week) after tumor implantation, whereas the siRNA-treated mice were killed later (after 4 weeks of tumor implantation). No significant secondary tumors were observed in mice treated with the siRNA-expressing plasmids, whereas control mice developed secondary tumors mostly at the diaphragm. Tumors were dissected, weighed, and the volume was measured. We noted a significant variation in the size and volume of the tumors in mice treated with siRNA Targeting MMP-9, uPAR, and cathepsin B AK Nalla et al plasmid when compared with control mice (Figure 7b ). Tumor volumes were measured using mathematical formula: (Figure 7c ). Although tumors treated with mono-cistronic plasmids (pM, pU, and PC) did inhibit tumor growth to a large extent, a remarkable reduction of B93 and 87% in tumor weight was observed in mice treated with bi-cistronic constructs, pUM, and pCM, respectively. Immunohistochemical analysis of prostate tumor sections revealed an increased expression of FAS-L and cleaved caspase-8 in tumors treated with siRNA constructs when compared with controls (Figures 7d and e) .
Discussion
Several studies that aimed to control cancer either by direct inhibition or blocking the activity of molecules associated with ECM degradation and angiogenesis were well documented. 9 Earlier work from our laboratory has shown the importance of the uPA system in prostate cancer metastasis both under in vitro and in vivo conditions. 42 Apart from the uPA system, therapeutic strategies targeting other proteases, especially MMP and cathepsins in prostate cancer cells were limited. Therefore, this study was aimed to knockdown MMP-9, uPAR, and CB in prostate cancer cells and to show the therapeutic potential of plasmid-based siRNA constructs. As a preliminary data, a comparison between the expression pattern of MMP-9, uPAR, and CB in three prostate cancer cell lines (PC3, DU145, and LNCaP) and their invasive ability showed a direct correlation between the MMP-9 enzymatic activity and uPAR expression with the invasive ability. PC3 and DU145 (androgen independent) cell lines, well known for their high metastatic behavior, expressed significantly high levels of uPAR and MMP-9 compared with LNCaP (androgen dependent), a poor 6 were re-suspended in 200 ml of PBS, fixed in 70% ethanol, and stored at À20 1C overnight. Cell pellet was re-suspended in 40 ml of phosphate-citrate buffer and incubated at room temperature for 30 min. The supernatant (DNA extract) was collected in new tubes after centrifugation. Three microliter aliquots each of 0.25% Nonidet P-40 and RNase A (1 mg ml À1 ) were added to the extracts and incubated at 37 1C for 1 h. Proteinase K was added to 100 mg ml À1 and incubation was continued for another hour. An aliquot of each DNA extract was analyzed on 1.5% agarose gel containing ethidium bromide by standard gel electrophoresis.
Targeting MMP-9, uPAR, and cathepsin B AK Nalla et al metastatic prostate cancer cell line. 42, 43 However, the CB levels were observed to be high in DU145 followed by LNCaP and PC3 cells. 44 Significance of higher CB expression in LNCaP than PC3 cells is yet to be understood. With the preliminary information, we further used PC3 and DU145 cells (metastatic prostate cancer cell Targeting MMP-9, uPAR, and cathepsin B AK Nalla et al lines), which expressed high levels of MMP-9 and uPAR compared with LNCaP cells. The aggressiveness in invasion and migration of the tumor cells determine the metastatic potential of the cancer. Several studies have shown the crucial role of the cellular proteases in tumor growth and metastasis. 14 In this study, we examined the functional importance of these cellular proteases in prostate cancer cell invasion and migration. Our studies have shown that the downregulation of MMP-9, uPAR, and CB using plasmids expressing siRNA significantly inhibited tumor invasion, migration as well as angiogenic ability of both PC3 and DU145 cells, indicating the active involvement of these molecules in tumor metastasis. Earlier studies have shown that downregulation of MMP-9 either using specific inhibitors, 45 antisense oligonucleotides, 46 or siRNA in breast tumor cells, 47 glioma, 48 and lung cancer cells inhibited tumor cell invasion and migration. Similarly, targeting uPA/uPAR system, either by inhibiting uPA activity or knockdown of uPA, uPAR expression, and blocking their interactions reduced tumor growth, invasion, and angiogenesis in various cancers. 15, 42 Our findings also confirm that downregulation of uPAR inhibited matrigel invasion, migration, and angiogenic Targeting MMP-9, uPAR, and cathepsin B AK Nalla et al ability of PC3 and DU145 cell lines. Inhibition of invasion, migration, and angiogenesis of uPAR knockout prostate cancer cells might be either due to decreased activation of uPA or due to the inhibition of downstream signaling caused by lateral interaction of uPAR with integrins. uPA, a serine protease produced as an inactive enzyme (pro-uPA), which on binding to uPAR becomes activated and cleaves plasminogen into plasmin. Further, the plasmin induces ECM degradation either by directly cleaving various extracellular proteins or by activating other proteases involved in the process. 15 Interestingly, we even noticed a preferential inhibition in the enzymatic activity of MMP-9 (a 92 kDa collagenase IV) but not MMP-2 (72 kDa collagenase IV) (see Figure 1d ) in uPAR and CB knockdown prostate cancer cell lines along with MMP-9 downregulated cells, indicating the specific role played by uPAR and CB in the activation of MMP-9. Among the several MMPs, MMP-9 is associated with cancer metastasis by degrading type IV collagen of basal lamina of basement membrane and thus aids in tumor invasion and angiogenesis in the tumor microenvironment. 22 Along with MMPs and the uPA/uPAR system, reports have even showed that both intra-and extracellular CB contribute to tumor invasiveness and its downregulation have inhibited the invasiveness of meningioma, 49 lung cancer cells, and glioma. 38 Similarly, we have also shown that downregulation of CB significantly inhibited invasive ability and migration of prostate cancer cell lines. Further, by comparing our results, it was clear that the simultaneous downregulation of two molecules using bi-cistronic vectors proved to be more effective in inhibiting cell invasion and migration than specifically targeting a single gene/molecule. The synergistic effect of bi-cistronic vectors indicates that each of these molecules might have specific and independent role in cell invasion, migration, and angiogenesis. Studies have also shown that the cellular proteases can either act independently as well as co-ordinate with other proteases in the process of tumor invasion and angiogenesis. 9, 50 Collectively, our present studies established the functional significance of MMP-9, uPAR, and CB in the prostate cancer cell lines. However, further studies are needed to understand the coordinated role played by each protease in tumor invasion.
Given our results showing the inhibition of tumor invasion and migration of the transfected prostate cancer cells, we studied the effect of MMP-9, uPAR, and CB downregulation on cell proliferation and the activation of intracellular signaling molecules. Among several signaling pathways, ERK and PI3-K/Akt pathways were well correlated with cancer cell growth, proliferation, differentiation, survival, and mobility. 16 Our results show that plasmid-based siRNA constructs inhibited the phosphorylation of Akt, a vital survival molecule that has an important function in cell proliferation and differentiation. In contrast to this, the ERK system was activated (that is phosphorylation of ERK), which was proposed to provide a protective effect against apoptosis. 51, 52 Even though majority of the reports indicate that the activation of ERK signaling pathway increases the apoptotic threshold of cancer cells, some studies have also shown the pro-apoptotic influence of ERK activation. 51, 53, 54 Recently, our results have shown that MMP-9 downregulation induces apoptosis after the activation of the ERK. Evidences were also provided to show that ERK activation has a vital function in MMP-9-mediated apoptosis. 55 This study also showed the apoptosis-inducing ability of the siRNA-mediated targeting of MMP-9, uPAR, and CB in prostate cancer cells. This was in accordance with several earlier reports on siRNA-mediated knockdown of these molecules in breast cancer, lung cancer, glioma, and so on. We have carried out DNA fragmentation and TUNEL assays to confirm apoptosis in the transfected cells. Apoptosis is majorly activated by either extrinsic or intrinsic pathways, which converge through activation of caspases and ultimately initiate cell death. Further evidence was provided by observing a decreased expression of anti-apoptotic molecules of Bcl-2 and XIAP, and enhanced expression of pro-apoptotic molecule such as Bax and activation (cleavage) of caspase-8 (initiator caspases) and caspase-7 (effector caspases). However, activation of caspase-3 was not seen. Similar to our observation, caspase-8-mediated apoptosis without caspase-3 activation was reported in uPAR and CB downregulated SNB19 glioma cells. 56 Activation of apoptosis might be due to the induction of intracellular death signaling process, which in turn might have stimulated the extracellular death signals released in MMP-9, uPAR, and CB downregulated prostate cancer cells. However, the death signal initiating mechanism is yet to be elucidated. With the activation of caspase-8, we made an attempt to elucidate the activation of Fas/Fasligand system in inducing apoptosis in siRNA-transfected prostate cancer cell lines. Several reports have shown that Fas/Fas-ligand system is enhanced in the cancer cells treated with anti-cancer chemotherapeutic agents. 57 Apart from chemotherapeutic agents, downregulation of MMPs was reported to induce Fas-mediated apoptosis and inhibit tumor progression in lung cancer 58 and breast cancer. 59 Similarly, in this study, the expressions of Fas-ligand as well as its receptor were enhanced in the siRNA plasmid transfected prostate cancer cells, providing further insight to the earlier reports. The increased expression of Fas-ligand/Fas in MMP-9, uPAR, and CB downregulated cells is yet to be understood. However, certain earlier reports also suggest that the presence of uPAR/uPA system (extracellular protease) might have a shielding effect on Fas receptor, which inhibits the activation of caspases-8. Fas-ligand functions both as autocrine as well as paracrine apoptotic mediator by binding to its receptor, Fas. On binding, the Fas/ Fas-ligand system associates in activation of the death domains, FADDs, by its ligation (oligomerization). 60, 61 This multiprotein death-inducing signaling complex could stimulate the activation of the initiator caspases, which in turn activates other effector caspases and progresses to apoptosis. 62, 63 The increased expression of Fas-ligand, Fas, FADD, cleavage of procaspase-8 (initiator caspases), and procaspase-7 (effector caspases)
Targeting MMP-9, uPAR, and cathepsin B AK Nalla et al supports the activation of extrinsic apoptotic pathway in MMP-9, uPAR, and CB downregulated prostate cancer cells. However, due to the enhancement of Bax and decrement of Bcl-2 proteins in the cell lysate of transfected cells, the involvement of intrinsic apoptotic pathway cannot be ruled out. Extended studies on both the apoptotic pathways might lead to the identification of new downstream targets useful for cancer treatment.
The induction of apoptosis and reduction in the invasive ability of prostate cancer cell lines in vitro provided us a platform to determine the efficiency of using siRNA plasmids in tumor regression under in vivo conditions. Earlier studies using antisense technology and the siRNA-mediated approach have been successfully used as targeting tools to suppress tumor development in animal models. Similarly in this study, we show that plasmids expressing siRNA for MMP-9, uPAR, and CB effectively regresses the in vivo established tumor growth and its migration to secondary sites (Figure 7a ). Furthermore, the bi-cistronic plasmids proved to be more effective in inhibiting tumor growth compared with the mono-cistronic plasmids.
In conclusion, our studies clearly show that the downregulation of MMP-9, uPAR, and CB in prostate cancer cell lines reduced tumor invasion and migration in both in vivo and in vitro conditions. Our in vivo results also revealed a significant reduction in tumor volume when treated with bi-cistronic siRNA plasmids, further indicating the potential of targeting two genes simultaneously using a same vector construct.
